- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03306316
Prebiotic in Preterm Infants
The Impact of Prebiotic on Growth, Feeding Progression and Neurodevelopment in Preterm Infants
This is a double blinded, randomized, controlled trial of prebiotic in infants born between 26 and 32 weeks gestational age. The investigators anticipate enrollment of 90 subjects in total and for the study to be completed in 18 months. The investigators anticipate collecting clinical data, anthropometrics, stool samples (requiring appropriate storage through analysis), salivary samples from mother and infant, discarded blood samples from baby after the standard care lab tests are done, a single, optional blood draw at the conclusion of the study, and subjecting infants to a neurodevelopmental survey at study completion.
The overall goal of this study is to test prebiotic administration to human milk-fed infants who are 700 gram to 1800 gram birthweight. The goal of this study will be addressed through one primary aim, a secondary aim, and exploratory aims, indicated below:
Primary aim: Compare weight, length, and head circumference Z-score growth between the study and placebo groups.
Secondary aim: Compare the time taken to achieve full feedings (135 mL/kg/day or more) between the study and placebo groups.
Exploratory aim 1: Compare neurobehavior, as measured by the validated Neonatal intensive care unit Network Neurobehavioral Scale (NNNS), between the study and placebo groups.
Exploratory aim 2: Compare fecal calprotectin levels to determine the impact of supplementation on reducing intestinal inflammation between the study and placebo groups.
Exploratory aim 3: Compare fecal microbiome between the prebiotic and placebo groups, to determine whether there is a shift in microbial composition towards bifidobacteria and other microbes that are capable of metabolizing prebiotic.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Ohio
-
Columbus, Ohio, United States, 43206
- Nationwide Children's Hospital and affiliated NICUs
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
Preterm infants who meet the following inclusion criteria will be eligible for randomization:
- Subjects will be preterm infants born 700 and 1800 g birthweight (inclusive), and >/=26 weeks to 31 6/7 weeks.
- Subject's parent(s) or legal guardian(s) have voluntarily signed and dated an informed consent form (ICF). They have also provided Health Insurance Portability and Accountability Act (HIPAA) (or other applicable privacy regulation) authorization prior to any participation in the study.
- Signed consent is obtained by day 10 after birth.
- Mother plans to provide her own milk or consents to use of donor human milk in NICU.
Exclusion Criteria:
Infants with the following conditions or situations at the time of randomization will be excluded from the study:
- Subject has known congenital anomalies.
- Administration of enteral clinical product must be initiated by 9 ± 2 days of life (birth date is day of life 0).
- Confirmed necrotizing enterocolitis (Bell's Stage II or III, Appendix J) or confirmed sepsis (positive culture requiring antibiotic treatment).
- Steroid use at time of randomization
- Mechanical ventilator dependence.
- >2 days of antimicrobial use prior to enrollment
- Maternal incapacity: including maternal opioids, cocaine or alcohol abuse during pregnancy or current
- Mother or infant is currently receiving treatment consistent with HIV therapy.
- Mother plans to formula feed exclusively and has not consented to use of donor milk during NICU stay.
- Infant with intraventricular hemorrhage
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Experimental
Experimental Arm
|
Prebiotic experimental group
Other Names:
|
Placebo Comparator: Control
Placebo Control Arm
|
Dextrose Control
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Weight
Time Frame: Enrollment through study day 45
|
Compare weight
|
Enrollment through study day 45
|
Length
Time Frame: Enrollment through study day 45
|
Compare length
|
Enrollment through study day 45
|
Head Circumference
Time Frame: Enrollment through study day 45
|
Compare head circumference
|
Enrollment through study day 45
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Adaptation
Time Frame: Enrollment through study day 45
|
Compare time to enteral autonomy
|
Enrollment through study day 45
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Neurobehavior
Time Frame: Enrollment through study day 45
|
Compare Neonatal intensive care unit Network Neurobehavioral Scale score
|
Enrollment through study day 45
|
Gut inflammation
Time Frame: Enrollment through study day 45
|
Compare gut inflammation by measurement of fecal calprotectin
|
Enrollment through study day 45
|
Fecal microbiome
Time Frame: Enrollment through study day 45
|
Compare fecal microbiome
|
Enrollment through study day 45
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- ColumbusCRI
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Development, Infant
-
Société des Produits Nestlé (SPN)RecruitingInfant Development | Growth and Development | Infant Health | Infant Formula | Infant Nutritional Physiological PhenomenaSaudi Arabia
-
University of ArizonaMead Johnson NutritionRecruiting
-
Hugo W. Moser Research Institute at Kennedy Krieger...Johns Hopkins UniversityNot yet recruitingChild Development | Developmental Delay | Infant Development | Language Development
-
Aussie Bubs, Inc.RecruitingInfant DevelopmentUnited States
-
Washington University School of MedicineUniversity of MinnesotaNot yet recruiting
-
Tokat Gaziosmanpasa UniversityRecruiting
-
University of Colorado, DenverRecruiting
-
Children's Hospital Los AngelesWuqu' Kawoq, Maya Health AllianceActive, not recruitingInfant DevelopmentGuatemala
-
ByHeartEnrolling by invitationInfant DevelopmentUnited States
-
Rontis Hellas SANational and Kapodistrian University of Athens; National Hellenic Research...Completed
Clinical Trials on Prebiotic
-
Beneo-InstituteUniversity of ReadingCompletedMoodUnited Kingdom
-
University of Maryland, BaltimoreNational Center for Complementary and Integrative Health (NCCIH)RecruitingSchizophrenia | Schizoaffective DisorderUnited States
-
University of CalgaryGeneral MillsCompleted
-
Rush University Medical CenterCures Within ReachCompletedPost Traumatic Stress DisorderUnited States
-
Hospital Universitari Vall d'Hebron Research InstituteCompleted
-
University of ChicagoRecruiting
-
Maastricht UniversityRecruiting
-
Rush University Medical CenterCompleted
-
Universitaire Ziekenhuizen KU LeuvenWithdrawn
-
Duke UniversityCompleted